Sanofi Adr (SNY)

01:00 AM

Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria - GlobeNewswire Inc.

01:00 AM

Apr 10, 2026

SNY Earnings History & Surprises | EPS & Revenue Results | SANOFI-ADR (NASDAQ:SNY) - ChartMill

Apr 10, 2026

Apr 07, 2026

Sanofi (SNY) Stock Price, News, Quote & History - Yahoo! Finance Canada

Apr 07, 2026

Apr 02, 2026

SNY Stock Price, Quote & Chart | SANOFI-ADR (NASDAQ:SNY) - ChartMill

Apr 02, 2026

Mar 31, 2026

Morgan Stanley lowers Sanofi stock price target on FX update - Investing.com UK

Mar 31, 2026

Mar 31, 2026

Morgan Stanley lowers Sanofi stock price target on FX update By Investing.com - Investing.com Canada

Mar 31, 2026

Mar 27, 2026

AstraZeneca Strengthens Position In COPD Race With Successful Trials - Sahm

Mar 27, 2026

Mar 25, 2026

Sanofi ADR (NASDAQ:SNY) Presents a Classic Value Investment Case - ChartMill

Mar 25, 2026

Mar 24, 2026

Sanofi S.A. stock faces pressure amid dividend payout and sector headwinds on Euronext Paris - AD HOC NEWS

Mar 24, 2026

Mar 21, 2026

Medicare Chief Chris Klomp Optimistic On CDC Director Search As Vaccine Fight Roils Agency— 'We Will Select...' - Sahm

Mar 21, 2026

Mar 17, 2026

Federal Judge Flags Legal Flaws In RFK Jr.'s Vaccine Overhaul - Sahm

Mar 17, 2026

Mar 11, 2026

Sanofi (NASDAQ:SNY) Emerges as a Top Dividend Stock from Methodical Screening - ChartMill

Mar 11, 2026

Mar 10, 2026

Dupixent Leads the Charge for Sanofi's Strong Portfolio in Immunology, Vaccines, and Rare Diseases - Morningstar

Mar 10, 2026

Mar 02, 2026

MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot - Finviz

Mar 02, 2026

Mar 02, 2026

Antibiotics Market - GlobeNewswire Inc.

Mar 02, 2026

Mar 01, 2026

Sanofi (SNY) and Regeneron's Dupixent Recommended for EU Approval - Finviz

Mar 01, 2026

Feb 27, 2026

Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway - Finviz

Feb 27, 2026

Feb 27, 2026

DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz

Feb 27, 2026

Feb 27, 2026

Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates - Finviz

Feb 27, 2026

Feb 26, 2026

How Do Investors Really Feel About Sanofi SA? - Sahm

Feb 26, 2026

Feb 25, 2026

CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans - Finviz

Feb 25, 2026

Feb 24, 2026

BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market - Finviz

Feb 24, 2026

Feb 23, 2026

Sanofi's (SNY) R&D Track Record Remains Investor Concern, Says BofA - Finviz

Feb 23, 2026

Feb 20, 2026

Manuela Buxo To Become Head of Sanofi's (SNY) Specialty Care Global Business Unit - Finviz

Feb 20, 2026

Feb 19, 2026

Teva And Sanofi Duvakitug Data Support IBD Pipeline And Growth Story - Sahm

Feb 19, 2026

Feb 17, 2026

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease - Sahm

Feb 17, 2026

Feb 16, 2026

RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell? - Finviz

Feb 16, 2026

Feb 13, 2026

SNY Stock Falls After Board Suddenly Makes Leadership Change - Finviz

Feb 13, 2026

Feb 12, 2026

Sanofi Pulls the Emergency Brake: What the Hudson Ouster and Garijo Appointment Really Mean for Investors - CTOL Digital Solutions

Feb 12, 2026

Feb 11, 2026

Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? - Finviz

Feb 11, 2026

Feb 10, 2026

SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status - Finviz

Feb 10, 2026